We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Gilead announced that it has 1.5 million individual doses of its antiviral remdesivir available for use as a COVID-19 treatment and will donate the doses when they’re needed. Read More
To keep prescription drugs moving smoothly through the supply chain during the pandemic, the FDA released emergency final guidance yesterday exempting certain COVID-19 products from tracing and identification requirements. Read More
Patients on a shorter dosing regimen in Gilead’s phase 3 remdesivir trial saw clinical improvements similar to those on the 10-day treatment schedule, the drugmaker announced Wednesday, offering hope of a COVID-19 treatment. Read More